Literature DB >> 25820334

Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.

Harinder Gill1, Cheuk-Him Man1, Alvin H W Ip2, William W L Choi2, Howard C H Chow1, Yok-Lam Kwong1, Anskar Y H Leung3.   

Abstract

Entities:  

Keywords:  FLT3-ITD; Sorafenib; acute myeloid leukemia; azacitidine

Mesh：

Substances：

Year:  2015        PMID： 25820334      PMCID： PMC4486234          DOI： 10.3324/haematol.2014.123034

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

2.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Authors:  Cheuk Him Man; Tsz Kan Fung; Christa Ho; Heron H C Han; Howard C H Chow; Alvin C H Ma; William W L Choi; Si Lok; Alice M S Cheung; Connie Eaves; Yok Lam Kwong; Anskar Y H Leung
Journal:  Blood       Date:  2012-02-24       Impact factor: 22.113

3.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

4.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Authors:  Jorge E Cortes; Hagop Kantarjian; James M Foran; Darejan Ghirdaladze; Mamia Zodelava; Gautam Borthakur; Guy Gammon; Denise Trone; Robert C Armstrong; Joyce James; Mark Levis
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

5.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Authors:  Oliver C Goodyear; Mike Dennis; Nadira Y Jilani; Justin Loke; Shamyla Siddique; Gordon Ryan; Jane Nunnick; Rahela Khanum; Manoj Raghavan; Mark Cook; John A Snowden; Mike Griffiths; Nigel Russell; John Yin; Charles Crawley; Gordon Cook; Paresh Vyas; Paul Moss; Ram Malladi; Charles F Craddock
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

6.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

7.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Authors:  Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

Authors:  Hubert Serve; Utz Krug; Ruth Wagner; M Cristina Sauerland; Achim Heinecke; Uta Brunnberg; Markus Schaich; Oliver Ottmann; Justus Duyster; Hannes Wandt; Thomas Fischer; Aristoteles Giagounidis; Andreas Neubauer; Albrecht Reichle; Walter Aulitzky; Richard Noppeney; Igor Blau; Volker Kunzmann; Reingard Stuhlmann; Alwin Krämer; Karl-Anton Kreuzer; Christian Brandts; Björn Steffen; Christian Thiede; Carsten Müller-Tidow; Gerhard Ehninger; Wolfgang E Berdel
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Naval Daver; Paolo Strati; Elias Jabbour; Tapan Kadia; Raja Luthra; Sa Wang; Keyur Patel; Farhad Ravandi; Jorge Cortes; Xiao Qin Dong; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2012-10-31       Impact factor: 10.047

Review 10.  FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.

Authors:  A Y H Leung; C-H Man; Y-L Kwong
Journal:  Leukemia       Date:  2012-07-16       Impact factor: 11.528
View more
  2 in total

Review 1.  [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors:  Ni-Na Wang; Qi-Dong Ye
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

Review 2.  Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.

Authors:  Harinder Gill; Anskar Y H Leung; Yok-Lam Kwong
Journal:  Int J Mol Sci       Date:  2016-03-24       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.